Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD).
Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in …

The development of PH in lung disease significantly worsens the morbidity and mortality of
patients with COPD and ILD. However, recent findings show importance of recognizing …

Tweetable abstract Pulmonary hypertension associated with ILD is a very severe condition.
The open label extension of the INCREASE trial demonstrates acceptable tolerability of …

Interstitial lung diseases (ILD) are a spectrum of disorders often complicated by pulmonary
hypertension (PH) in its course. The pathophysiologic mechanism of WHO group 3 PH is …

Idiopathic pulmonary fibrosis (IPF) represents a fibrotic interstitial lung disease characterized
by uncertain etiology and poor prognosis. Over the years, the path to effective treatments …

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) is an attractive
target for clinical trials of PH medications. There are many factors that need to be considered …

Objectives Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary
arterial hypertension, manifesting a significant reduction in morbidity and mortality …

The prevalence of pulmonary hypertension (PH) complicating interstitial lung diseases
(ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung …

Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered
complication of fibrotic ILDs, is associated with significant morbidity and mortality. Until …

This article provides a comprehensive overview of the latest literature on the diagnostics and
treatment of pulmonary hypertension (PH) associated with interstitial lung disease (ILD) …